What’s next in remyelination therapy?
- Remyelination substances currently under observation include the following (see Multiple Sclerosis Journal for details):
New imaging technologies are under development to measure remyelination efficacy, including:
- diffusion tensor imaging (DTI)
- magnetized transfer imaging (MTI)
- myelin water fraction imaging (MWF)
- positron emission tomography (PET)
The authors of “Remyelination in Multiple Sclerosis – How Close are We?” in the Journal of Neurology & Neurophysiology assert that:
“If we can provide our MS patients with drugs promoting remyelination, we will be changing the natural history of the disease. That is why it makes sense to think about this, as a much-needed therapeutic strategy.”
Remyelination therapy is not a cure, but can bring hope and maybe even a reversal of symptoms for many who are severely disabled by MS.
Does the prospect of remyelination therapy intrigue you? What questions do you have about this novel approach? Post your replies in the comments below or at the original “New MS Therapy Company to Focus on Rejuvenating Coating That Protects Nerve Cells” forum entry.
***
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.